At Peptid24 we classify compounds soberly by receptor profile and mechanism of action. Retatrutide belongs to the newest generation of experimental research peptides: instead of targeting a single hormone receptor, it activates three at once — GLP-1, GIP and Glucagon. This triple profile is what makes Retatrutide particularly interesting for metabolic research.
How does Retatrutide work?
GLP-1 axis
Activates glucose-dependent insulin secretion, suppresses glucagon release and slows gastric emptying.
GIP axis
Further amplifies the insulinotropic response and is involved in fat and bone metabolism — a pathway missing from pure GLP-1 compounds.
Glucagon axis
Influences energy metabolism via hepatic pathways — this third pathway distinguishes Retatrutide from dual agonists.
The interplay of all three pathways is a central focus of current research into multi-receptor agonists.
Research status
Retatrutide is currently in clinical trials and is not approved. It is one of the most studied compounds in current multi-receptor agonist research.
Scientific sources
- Jastreboff AM, et al.: “Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial.” N Engl J Med. 2023. PubMed (PMID 37366315)
- Study registration: ClinicalTrials.gov, NCT04881760
Retatrutide in comparison
Storage & shelf life
Retatrutide ships as a lyophilised (freeze-dried) powder and stays stable in this state when kept dry, dark and at 2–8°C. After reconstitution with a suitable sterile solvent, we recommend keeping the solution refrigerated at all times and using it within 4 weeks. See our Storage Guide for details.
Retatrutide at Peptid24
Peptid24 carries Retatrutide in 10, 20, 30 and 40 mg — every batch HPLC-verified to ≥98.9% purity, including a Certificate of Analysis (COA).